Use of ligation adhesion molecule-like proteins as biomarkers and therapeutic targets in invasive candidiasis
By using ligation adhesion molecule-like protein (JAML) as a biomarker and therapeutic target, the limitations of invasive candidiasis were solved, achieving more accurate diagnosis and more effective therapeutic effects, significantly improving Patient survival and renal function.
Patent Information
- Application Number
- CN202411143503.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art has limitations in the diagnosis and treatment of aggressive candidiasis, especially the low sensitivity of diagnostic methods and the limitation of therapeutic drugs, resulting in high mortality and difficulty in treatment.
Using ligation adhesion molecule-like protein (JAML) as a biomarker and therapeutic target to develop new diagnostic reagents and therapeutic drugs to assist in the diagnosis and monitoring of the severity of Candida infection by measuring JAML expression in bodily fluid samples , and improves the body's fungal clearance ability and reduces kidney damage through JAML recombinant protein.
Effectively improve the diagnostic accuracy and therapeutic effect of invasive candidiasis. Through the use of JAML, the severity and prognosis of the disease can be predicted, and the survival rate and renal function of mice are significantly improved, providing a new biomarker and potential treatment. Target.
Smart Images

Figure CN119023971A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to the use of junctional adhesion molecule-like protein as a biomarker and therapeutic target in invasive candidiasis. Background Art
[0002] Invasive candidiasis (IC) is the fourth most common blood-borne infectious disease in hospitals. Due to the lack of ideal diagnostic methods and inadequate antifungal treatment, the mortality rate of IC is as high as 46% to 75%.
[0003] Regarding the causes of infection, the most common patients with the infection are critically ill patients in the intensive care unit (ICU), patients undergoing abdominal surgery, and patients with neutropenia. However, a sharp increase in Candida species in patients admitted to medical wards in one country has recently been reported. This may be due to a greater awareness of this infection among physicians working in medical wards or the increasing number of elderly patients admitted to hospitals who have many risk factors for invasive candidiasis, such as indwelling central venous catheters, peripheral parenteral nutrition (PPN), total parenteral nutrition (TPN), urinary catheters, and broad-spectrum antibiotic therapy. In addition, the elderly often have multiple comorbidities such as diabetes, cirrhosis, solid tumors, and malnutrition, which are more similar to very complex ICU patients. Interestingly, the increasing prevalence of Clostridium difficile infection and carbapenemase-producing Klebsiella pneumoniae colonization in elderly patients with frequent hospitalizations has been suggested as a possible new factor associated with the pathogenesis of candidiasis.
[0004] In terms of diagnosis, culture is the gold standard for IC diagnosis, but due to its low sensitivity and long detection time, it is far from meeting clinical needs. In recent years, IC diagnostic research targeting Candida antigens, antibodies and nucleic acids has made great progress, but due to their own defects, these methods still face great difficulties in clinical application. For example, in antigen detection, since the antigen composition of Candida is very complex, there is a wide range of cross-talk with various substances in nature, such as hemoglobin, albumin, nitrocellulose membrane for hemodialysis, polysaccharide immunomodulators, bacteria, other fungi, rheumatoid factors, etc., which can easily lead to false positive results. In addition, after the antigen is combined with the antibody in the circulation, it is quickly cleared by the body's immune system, which makes the sensitivity of antigen diagnosis low, resulting in false negative results. At present, there is still a lack of IC-specific antigen detection methods in clinical practice. The G experiment detects invasive infections caused by various fungi. However, the existing IC antigen diagnosis research has unreasonable experimental design, too small sample size, or only animal model results.
[0005] In terms of treatment, regarding the treatment of confirmed infections, the latest Infectious Diseases Society of America (IDSA) and European guidelines recommend the use of echinocandin as the first-line treatment for Candida infections instead of fluconazole. The evidence supporting this recommendation is mainly based on the increasing prevalence of fluconazole-resistant Candida strains and previously described clinical trials in which echinocandin showed significantly higher efficacy than azole drugs in the treatment of candidiasis. Interestingly, when antifungal treatment was given to critically ill patients with septic shock caused by Candida, the administration of echinocandin was also associated with better survival, which was related to timely and adequate source control. Despite the increasing evidence of the superiority of echinocandin, fluconazole remains an acceptable alternative for patients with candidiasis who are not critically ill or not at risk of fluconazole resistance. Moreover, there are some limitations to the use of echinocandin in the treatment of invasive candidiasis, such as: First, echinocandin is not the first choice in infections in certain specific sites, including the central nervous system, eyes, and urinary system. This is mainly because the concentration of echinocandin in these areas is not high. Secondly, the minimum inhibitory concentration (MIC) of echinocandin for Candida parapsilosis is higher than that of fluconazole, which raises concerns about the efficacy of echinocandin against Candida parapsilosis. Finally, although uncommon, resistance to echinocandin has been found in Candida glabrata and Candida krusei. In addition, since the epidemiology of Candida pathogens in my country is different from that in Europe and the United States, it is still valuable to choose fluconazole as the initial treatment.
[0006] It can be seen that the current diagnosis and treatment methods of IC have certain limitations. Therefore, finding new methods for the diagnosis and treatment of invasive candidiasis and breaking through the limitations of existing technologies is still a topic that needs to be continuously studied in depth. Summary of the invention
[0007] In view of the above-mentioned shortcomings of the prior art, the purpose of the present invention is to provide the use of junctional adhesion molecule-like protein (JAML) as a biomarker and therapeutic target in invasive candidiasis, to provide a new biomarker JAML for the diagnosis, prognosis and efficacy evaluation of Candida infection and diseases caused by it, and to reflect the severity of the disease, and to provide a new technical means for the treatment of Candida infection and diseases caused by it.
[0008] To achieve the above objectives and other related objectives, the present invention provides, in a first aspect, the use of JAML as a biomarker in the preparation of diagnostic reagents, prognostic reagents or efficacy evaluation reagents for Candida infection and / or diseases caused by Candida infection.
[0009] In some embodiments, the diseases caused by Candida infection include but are not limited to bloodstream infection and invasive candidiasis caused by Candida infection.
[0010] In some embodiments, the Candida includes but is not limited to Candida albicans (C.albicans), Candida parapsilosis (C.parapsilosis), Candida glabrata (C.glabrata), Tropical candida (C.tropicalis), Candida metapsilosis (C.metapsilosis), Candida krusei (C.krusei), Candida lusitaniae (C.lusitaniae), etc.
[0011] In some embodiments, the reagent is used to determine the expression level of JAML in a body fluid sample.
[0012] In some embodiments, the method for detecting the expression level of JAML by the reagent includes but is not limited to chemiluminescence, enzyme-linked immunosorbent assay, immunoturbidimetry, immunofluorescence, colloidal gold method, electrochemistry, microfluidics, high-throughput technology, etc.
[0013] In some embodiments, the expression level of JAML in the body fluid sample is negatively correlated with the severity of Candida infection and / or a disease caused by Candida infection.
[0014] In some embodiments, the body fluid sample is selected from at least one of serum, plasma, whole blood, urine, cerebrospinal fluid, pleural effusion, ascites, and joint fluid.
[0015] In some embodiments, the reagent is used to assist in the diagnosis or monitoring of the presence and / or course and / or severity and / or risk of death and / or prognosis of Candida infection and / or a disease caused by Candida infection.
[0016] In some embodiments, the instructions for use of the reagent record a preset threshold value, and the severity and / or risk of death and / or prognosis of Candida infection and / or diseases caused by Candida infection are judged by comparing the expression amount of JAML obtained by the determination with the preset threshold value. In a specific embodiment, when the concentration of JAML obtained by the determination is lower than the preset threshold value, the severity and / or risk of death of Candida infection and / or diseases caused by Candida infection increase; when the concentration of JAML obtained by the determination is higher than the preset threshold value, the severity and / or risk of death of Candida infection and / or diseases caused by Candida infection decrease, and / or the prognosis is good, and / or the survival rate is improved. Exemplarily, the preset threshold value can be 2900pg / ml, but is not limited thereto, and can be further studied on the basis of the present invention or selected and determined according to actual conditions.
[0017] The second aspect of the present invention provides use of JAML in the preparation of a medicament for improving and / or treating Candida infection and / or a disease caused by Candida infection.
[0018] In some embodiments, the active ingredient of the drug includes at least one of the following components: JAML, JAML recombinant protein, a product obtained after certain / some chemical modifications of JAML, and a product obtained after certain / some chemical modifications of JAML recombinant protein. The chemical modification will change the structure of the protein, thereby affecting the stability, biological activity and function of the protein, but will not affect the main function of the protein. At the same time, the purpose of the chemical modification is to further effectively control and improve the quality and safety of the drug, for example, oxidation modification, glycosylation, phosphorylation, acetylation, etc.
[0019] Furthermore, the drug has at least one of the following effects (I) to (II):
[0020] (Ⅰ) Enhance the body's ability to eliminate fungi;
[0021] (Ⅱ) Reduce kidney damage in the body.
[0022] Further, when the drug is used, the effective dose of the active ingredient is 50-500 μg / kg body weight, preferably 100-500 μg / kg body weight, more preferably 200-500 μg / kg body weight, and most preferably 300-500 μg / kg body weight, such as 300, 350, 400, 450, 500 μg / kg body weight. This part of the data comes from animal experiments, and the dose may be quite different when used in humans or other animals. Therefore, when the active ingredient of the drug is used to treat Candida infection and diseases caused by it, its effective dose includes but is not limited to the above range.
[0023] In some embodiments, the drug may be a single-component substance or a multi-component substance.
[0024] In some embodiments, the drug further comprises a pharmaceutically acceptable carrier and / or excipient.
[0025] In some embodiments, the form of the drug is not particularly limited and can be in various forms such as solid, liquid, gel, semi-fluid, aerosol, etc.
[0026] In some embodiments, the drug is mainly targeted at mammals, and the mammals are preferably rodents, even-toed ungulates, perissodactyls, lagomorphs, primates, etc., and the primates are preferably monkeys, apes or humans.
[0027] In some embodiments, the drug can be administered in a variety of forms, such as enteral administration or parenteral administration. It is generally recommended to administer the drug in a known route, such as intravenous injection, intraperitoneal injection, etc.
[0028] As described above, the use of JAML of the present invention as a biomarker and therapeutic target in invasive candidiasis has the following beneficial effects:
[0029] On the one hand, the present invention found that the JAML content in the serum of patients with clinical invasive candidiasis was significantly higher than that in healthy people, and the JAML content in the serum of patients with clinical invasive candidiasis was negatively correlated with the severity of the disease. Therefore, it is proposed that JAML can be used as an indicator for the diagnosis, prognosis and efficacy evaluation of invasive candidiasis, and can also predict the severity of invasive candidiasis.
[0030] On the other hand, the present invention found that administration of exogenous JAML recombinant protein can significantly improve the survival rate of mice with invasive candidiasis, enhance the body's fungal clearance ability, and reduce renal damage. Therefore, it is proposed that it can be used as a potential therapeutic target for the clinical treatment of invasive candidiasis.
[0031] In summary, the present invention provides JAML as a new biomarker for the diagnosis, prognosis and efficacy evaluation of Candida infection and diseases caused by it, and reflects the severity of the disease. At the same time, it can also serve as a potential therapeutic target, providing a new technical means for the treatment of Candida infection and diseases caused by it. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Shown is the expression level of JAML in the serum of candidemia patients and healthy controls in Example 1 of the present invention.
[0033] Figure 2A and 2B show the comparison results of the renal injury indicators Urea and Crea of candidemia patients and healthy controls in Example 2 of the present invention, Figure 2 C and 2D show the correlation analysis results of the JAML content in the serum of candidemia patients and healthy controls and renal injury indicators (Urea, Crea) in Example 2 of the present invention.
[0034] Figure 3 A shows the serum JAML content of patients who died of candidemia and patients who survived in Example 3 of the present invention, Figure 3 B shows the comparison of survival curves related to JAML content.
[0035] Figure 4 A and 4B respectively show the positive and death diagnosis statistics of JAML, Urea and Crea in invasive Candida infection in ROC curve analysis in Example 4 of the present invention.
[0036] Figure 5 A shows the survival curve of wild-type mice in the JAML experimental group and the PBS control group in Example 5 of the present invention, Figure 5 B shows the body weight change trend of wild-type mice in the JAML experimental group and the PBS control group.
[0037] Figure 6 A shows the Candida load statistics of the kidneys of wild-type mice in the JAML experimental group and the PBS control group after 4 days in Example 6 of the present invention. Figure 6 B and 6C show the statistical graphs of the expression levels of Urea and Crea in the serum of wild-type mice in the JAML experimental group and the PBS control group after 4 days in Example 6 of the present invention.
[0038] Figure 7 A shows the pathological sections of the kidneys of wild-type mice in the adhesion molecule-like protein experimental group and the PBS control group after 4 days in Example 7 of the present invention. Figure 7 B is the statistical analysis results of pathological scores. DETAILED DESCRIPTION
[0039] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0040] The present invention focuses on exploring the application value of JAML in invasive candidiasis.
[0041] Junctional adhesion molecule-like protein (JAML), also known as AMICA, is a 65 kDa, type I transmembrane glycoprotein that belongs to the junctional adhesion molecule (JAM) subgroup of the immunoglobulin superfamily. JAM family proteins contribute to intercellular junctions within epithelial and endothelial cell layers and mediate their interactions with various hematopoietic cells. Mouse JAML cDNA encodes a 379 amino acid (aa) precursor that includes a 20 aa signal sequence, a 261 aa extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 77 aa cytoplasmic domain. In contrast to other JAM family proteins, JAML does not contain a cytoplasmic PDZ binding motif. JAML is expressed on the surface of granulocytes and monocytes and is upregulated during differentiation of myeloid leukemic cells. JAML mediates the adhesion of monocytes to endothelial cells and the migration of neutrophils across epithelial cell monolayers.
[0042] JAML was initially identified as a major co-stimulatory molecule in epithelial γδ-T cells and is activated by the coxsackie and adenovirus receptor (CXADR), whose ligand is expressed by epithelial cells and has been shown to be important for tissue homeostasis and wound repair. Although JAML has an overall low sequence identity (11%) to the co-stimulatory molecule CD28, its intracellular signaling motifs share great similarities and, upon ligation, recruit phosphatidylinositol-3-kinase (PI3K) for cell activation, proliferation, and cytokine production. In addition, JAML has been suggested as an attractive cancer immunotherapy target in mouse models.
[0043] In recent years, new aspects of cellular JAM functions and their underlying molecular mechanisms are emerging. Notably, the roles of JAM family members in lipid metabolism and disorders related to dysregulation have attracted attention. JAM-A knockout mice fed a diet high in saturated fat, fructose, and cholesterol (HFCD) develop more severe non-alcoholic steatohepatitis. Here, among the JAM-family members, including JAM-A (JAM-1), JAM-B (JAM-2), JAM-C (JAM-3), JAM-4, and JAML (junctional adhesion molecule-like protein), the researchers found that JAML is a new member of the JAM family that mediates leukocyte adhesion and transendothelial migration and is more highly expressed in the kidneys of diabetic mice. In addition, podocyte-specific deletion of JAML improves podocyte injury and proteinuria. The researchers further demonstrated a novel role for JAML in regulating podocyte lipid metabolism through the SIRT1-mediated SREBP1 signaling pathway. Similar results were found in doxorubicin (ADR) nephropathy mice. Importantly, it was also observed that JAML levels were higher in the glomeruli of patients with various proteinuric kidney diseases and were positively correlated with lipid accumulation, but negatively correlated with the glomerular filtration rate of these individuals. These results suggest that JAML may be an attractive therapeutic target for DKD or other proteinuric kidney diseases. However, no studies on JAML in invasive candidiasis have been reported. The present invention has found through a series of explorations that JAML, as a new cytokine, is involved in the diagnosis and prognosis of invasive Candida infection, providing a new diagnostic method for clinical practice. At the same time, it can also serve as a potential therapeutic target for invasive candidiasis, providing new technical means for the treatment of invasive candidiasis.
[0044] The inventors of the present application used an enzyme linked immunosorbent assay (ELISA) method to detect the serum of 65 patients with candidemia and 65 patients with negative pathogen detection, and found that the JAML level in patients with candidemia was significantly higher than that in healthy controls, and there was a significant statistical difference. Further analysis of the JAML change levels of dead patients and surviving patients found that JAML was lowly expressed in dead patients and had a statistical difference compared with surviving patients. Survival curve analysis found that JAML promoted the death of invasive candidemia patients when it was lowly expressed. Subsequently, the receiver operating characteristic curve (ROC curve) was used to analyze the diagnostic value of JAML, urea (Urea), and creatinine (Crea) in invasive fungal infections, and it was found that the area under the curve covered by the marker Urea was the largest, followed by JAML, and the area under the JAML curve was higher than Crea, indicating that JAML can be used as a diagnostic indicator for invasive Candida infection.
[0045] Furthermore, the inventors of the present application found through the study of the invasive candida infection mouse model that the use of Candida albicans infection can cause an increase in the expression level of JAML in mice. Treatment with JAML recombinant protein can significantly improve the survival rate of mice infected with invasive candidiasis, and the bacterial load and renal function of mice in the treatment group are significantly improved, which shows that JAML recombinant protein enhances the fungal clearance function of mice infected with invasive candidiasis and reduces renal damage. The above results show that supplementation with JAML can reduce pathological damage to the kidneys and improve the quality of life of the host. Therefore, the expression level of JAML can be used as an indicator to assess the severity of the disease and can be used as a potential therapeutic target.
[0046] The implementation of the present invention is further described in detail below through specific examples.
[0047] Example 1
[0048] Determination of JAML expression in serum of patients with candidemia
[0049] The inclusion criteria for patients with invasive candidiasis infection are positive blood culture for Candida albicans. The blood specimens used in this embodiment and the following embodiments are tested for relevant pathogens by the microbiology laboratory of the laboratory department. After the test confirms that it is Candida bloodstream infection, the serum specimens of the patient on the day of the test are collected. At the same time, the serum specimens of the physical examinees with negative pathogen tests are collected in the laboratory department as healthy controls. The exclusion criteria for the physical examinee population with negative pathogen tests are patients with underlying diseases such as cancer, diabetes, autoimmune diseases, and other acute and chronic infections that affect JAML expression; serum specimens are immediately frozen in a -80°C refrigerator after collection for subsequent experiments; the patient's basic personal information, hospitalization days, renal function indicators, infected bacteria, etc. are fully recorded. All serum samples were divided into three groups: candidemia group, bacterial sepsis group, and healthy control group. The concentration of JAML in serum samples of 65 candidemia patients, 65 bacterial sepsis patients, and 65 pathogen-negative subjects was detected by ELISA. The kit used for the detection was a human JAML ELISA kit (the kit was purchased from R&D Systems, lot number: Lot P306883). The specific operation steps strictly refer to the kit instructions. GraphPad Prism 8.0.2 software was used for statistical analysis and plotting.
[0050] Figure 1 Shown is the expression level of JAML in the serum of candidemia patients and healthy controls.
[0051] like Figure 1As shown in the results, the expression of JAML in the serum of patients with candidemia was significantly higher than that of healthy controls, and the difference was statistically significant (P<0.05). Therefore, JAML can be used as a diagnostic indicator for clinical invasive candidiasis.
[0052] Example 2
[0053] Serum JAML concentration is negatively correlated with renal injury in patients with candidemia
[0054] According to research reports, in the case analysis of human infection with invasive Candida and the mouse invasive fungal infection model, the kidney is the main target organ of Candida infection. Therefore, this embodiment evaluates the severity of the disease by evaluating the damage index of the kidney in patients with candidemia. The renal function index Urea and Crea data of candidemia patients and healthy controls were collected and compared through the LIS system of the laboratory department, and the renal function index Urea, Crea and the corresponding serum JAML of each candidemia patient / healthy control were analyzed for expression correlation, and GraphPad Prism 8.0.2 software was used for correlation analysis and plotting.
[0055] Figure 2 A and 2B show the comparison results of renal injury indicators Urea and Crea in candidemia patients and healthy controls. Figure 2 C and 2D show the results of correlation analysis between the JAML content in the serum of candidemia patients and healthy controls and renal injury indicators (Urea, Crea).
[0056] like Figure 2 As shown in A and 2B, the renal function indicators Urea and Crea in patients with candidemia were significantly higher than those in healthy controls, and were statistically significant (P<0.0001 and P<0.01). Figure 2 As shown in Figures C and 2D, the correlation analysis between the renal function indicators Urea and Crea and JAML expression showed that the correlation coefficient between JAML and Urea was r = -0.3311, P = 0.0453; the correlation coefficient between JAML and Crea was r = -0.3741, P = 0.0499, which was statistically significant. The above results suggest that JAML is negatively correlated with renal damage in patients with candidemia.
[0057] Example 3
[0058] Comparison of serum JAML levels between patients who survived candidemia and those who died, and analysis of JAML concentration and patient survival curve
[0059] The statistical analysis of Example 2 found that JAML was negatively correlated with the degree of renal damage in patients with candidemia, so the final disease outcome of patients with candidemia was continuously followed. According to all the patient medical records in the LIS system of the laboratory department, 48 patients with candidemia were divided into two groups: non-survivors and survivors, including 15 non-survivors and 33 survivors, and the changes in the concentration of JAML in their serum were compared; the correlation calculation of the predicted death and survival patients based on the concentration of JAML was used as the cut-off value, and the survival days of the patients were statistically analyzed to draw the Kaplan Meier survival rate curve, and the GraphPad Prism8.0.2 software was used for statistical analysis and drawing.
[0060] Figure 3 Shown is a comparison of serum JAML levels and survival curves between patients who died of candidemia and those who survived.
[0061] Figure 3 In A, the serum JAML concentration of the surviving patients with candidemia was significantly higher than that of the dead patients, and the difference was statistically significant; Figure 3 The survival rate curve based on the survival days of patients with candidemia in B indicates that when the JAML concentration is lower than 2900pg / ml, the patient mortality rate increases, while when the JAML concentration is higher than 2900pg / ml, the patient survival rate is better. The above results indicate that in patients with invasive candidiasis, the level of JAML in serum reflects the severity of the patient's disease and is related to the patient's final survival outcome.
[0062] Example 4
[0063] ROC curve analysis to compare the diagnostic efficacy of serum JAML, Urea, and Crea in patients with positive and dead invasive Candida infection
[0064] The laboratory indicators Crea and Urea test values of candidemia patients and healthy controls were collected through the laboratory LIS system. Using the data of JAML, Urea and Crea, GraphPad Prism 8.0.2 software was used to draw and analyze the ROC curve and draw a graph to analyze and compare the diagnostic efficacy of the three types of indicators for candidemia-positive patients and candidemia-dead patients, and GraphPad Prism 8.0.2 software was used to draw and analyze the ROC curve and draw a graph.
[0065] Figure 4 A and 4B show the positive and death diagnostic statistics of JAML, Urea and Crea in invasive Candida infection, respectively.
[0066] Table 1. Comparison of the correlation between JAML / Urea / Crea in predicting candidemia-positive patients by ROC curve analysis
[0067]
[0068] Table 2. Comparison of the correlation between JAML / Urea / Crea in predicting candidemia deaths by ROC curve analysis
[0069]
[0070] like Figure 4 As shown in A and Table 1 , the ROC curve analysis of the diagnostic value of different indicators in patients with positive candidemia showed that the areas under the curve of serum JAML, Urea, and Crea were 0.6516, 0.8652, and 0.6190, respectively; Figure 4 B and Table 2 show that the ROC curve analysis of different indicators in the diagnosis of invasive candidemia in patients with death, the area under the curve of serum JAML, Urea and Crea were 0.6885, 0.7779 and 0.6190, respectively. From the statistical results, it was found that the area under the curve of JAML was lower than that of Urea but significantly greater than that of Crea, and it was statistically significant, indicating that JAML has a certain prognostic monitoring value for invasive Candida positive infection.
[0071] Example 5
[0072] Supplementation of exogenous JAML recombinant protein can significantly improve the survival rate of mice infected with Candida albicans
[0073] Twenty-two wild female C57BL / 6J mice aged 6-8 weeks and weighing 21-22 g (purchased from Chongqing Enswell Biotechnology Co., Ltd.) were randomly selected as the JAML experimental group and 23 as the PBS control group. The wild-type mice in the JAML experimental group were intraperitoneally injected with 8 μg of mouse JAML recombinant protein (purchased from MCE, HY-P76464) with PBS as the protein solvent. The wild-type mice in the PBS control group were intraperitoneally injected with an equal amount of protein solvent PBS. Half an hour later, the wild-type mice in the JAML experimental group and the PBS control group were intraperitoneally injected with a high-dose Candida albicans suspension (3×10 5 cfu), and then observe and record the changes in survival rate every day, analyze and plot using GraphPadPrism 8.0.2 software, and draw the Kaplan Meier survival curve.
[0074] Figure 5 A shows the survival curves of wild-type mice in the JAML experimental group and the PBS control group.
[0075] like Figure 5As shown in A, after wild-type mice were intraperitoneally injected with mouse-derived JAML recombinant protein to increase JAML in vivo, the Candida albicans model was observed for 20 days. It was found that compared with mice injected with mouse-derived JAML recombinant protein intraperitoneally, the survival time of wild-type mice in the PBS control group was significantly shorter than that in the experimental group. This shows that the injection of mouse-derived JAML recombinant protein significantly improved the survival of mice with candidemia and delayed the time of death. The above results suggest that JAML recombinant protein has the potential to treat invasive candidiasis infection, and JAML is a therapeutic drug that limits the occurrence and development of candidemia.
[0076] Figure 5 B shows the body weight change curve of wild-type mice in the JAML experimental group and the PBS control group.
[0077] like Figure 5 As shown in B, after wild-type mice were intraperitoneally injected with mouse-derived JAML recombinant protein to increase JAML in vivo, the Candida albicans model was observed for 10 days. It was found that the weight of wild-type mice in the PBS control group decreased faster than that of mice injected intraperitoneally with mouse-derived JAML recombinant protein. The above results also confirm the protective effect of JAML on mice infected with Candida albicans.
[0078] Example 6
[0079] Bacterial load and renal function index detection experiment
[0080] Referring to the method of Example 5, 5 JAML experimental groups and 5 PBS control groups were constructed. After 4 days of feeding, 5 mice were taken from each of the JAML experimental group and the PBS control group, and heart blood was taken after anesthesia. The supernatant was taken after centrifugation, and the renal function indicators Urea and Crea were detected. The mouse kidneys were taken, ground into a homogenate with 1 ml of sterile PBS and then diluted 50-200 times. Subsequently, 5 μl was taken for plating, and the number of colonies on the Sabouraud plate was counted after 20 hours.
[0081] Figure 6 A shows the statistical graph of Candida load in the kidneys of wild-type mice in the JAML experimental group and the PBS control group after 4 days; Figure 6 B and 6C show the statistical graphs of Urea and Crea expression levels in the serum of wild-type mice in the JAML experimental group and PBS control group after 4 days, respectively.
[0082] like Figure 6 As shown in A, compared with the control group, after administration of exogenous JAML recombinant protein, the Candida load in the kidneys of wild-type mice was significantly reduced, and there was a statistical difference, indicating that JAML enhanced the body's fungal clearance ability; as shown in 6B and Figure 6As shown in C, the expression levels of renal function indicators Urea and Crea in mice given exogenous JAML recombinant protein on the 4th day after Candida infection were significantly lower than those in the PBS control group, and the difference was statistically significant, indicating that JAML improved the renal function of mice.
[0083] Example 7
[0084] Renal pathology results
[0085] Referring to the method of Example 5, 5 JAML experimental groups and 5 PBS control groups were constructed. After 4 days of feeding, the kidneys were removed under anesthesia, fixed with paraformaldehyde, and sliced for pathological staining, and the results were scored pathologically.
[0086] like Figure 7 As shown in A, compared with the control group, 4 days after Candida infection, the renal pathological sections of mice given exogenous JAML recombinant protein showed better renal status compared with wild-type mice in the PBS control group; Figure 7 As shown in B, the renal pathology score of mice given exogenous JAML recombinant protein was lower than that of wild-type mice in the PBS control group, with a statistically significant difference (P<0.01).
[0087] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. Use of a conjugated adhesion molecule-like protein as a biomarker in the preparation of a diagnostic reagent, a prognostic reagent or an efficacy evaluation reagent for Candida infection and / or a disease caused by Candida infection.
2. The use according to claim 1, characterized in that: The diseases caused by Candida infection include bloodstream infection and invasive candidiasis caused by Candida infection.
3. The use according to claim 1, characterized in that: The reagent is used to determine the expression amount of the junctional adhesion molecule-like protein in a body fluid sample.
4. The use according to claim 3, characterized in that: The method for detecting the expression amount of the connecting adhesion molecule-like protein by the reagent is selected from at least one of chemiluminescence, enzyme-linked immunosorbent assay, immunoturbidimetry, immunofluorescence, colloidal gold method, electrochemistry, microfluidics technology and high-throughput technology.
5. The use according to claim 3, characterized in that: The expression level of the JAM-like protein in the body fluid sample is negatively correlated with the severity of Candida infection and / or the disease caused by Candida infection.
6. The use according to claim 1, characterized in that: The reagent is used for assisting diagnosis or monitoring the existence and / or course and / or severity and / or mortality risk and / or prognosis of Candida infection and / or diseases caused by Candida infection.
7. Use of a junctional adhesion molecule-like protein in the preparation of a drug for improving and / or treating Candida infection and / or diseases caused by Candida infection.
8. The use according to claim 7, characterized in that: The active ingredients of the drug include at least one of the following components: connecting adhesion molecule-like protein, connecting adhesion molecule-like protein recombinant protein, a product obtained after certain / certain chemical modifications of the connecting adhesion molecule-like protein, and a product obtained after certain / certain chemical modifications of the connecting adhesion molecule-like protein recombinant protein.
9. The use according to claim 7 or 8, characterized in that: The drug has at least one of the following effects (I) to (II): (Ⅰ) Enhance the body's ability to eliminate fungi; (Ⅱ) Reduce kidney damage in the body.
10. The use according to claim 7 or 8, characterized in that: The medicine further comprises a pharmaceutically acceptable carrier and / or excipient.
